Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP625512.RAozAv84XSIpZ2idlhDjohv_JpQdfV9B1CQP_a0w81jx8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP625512.RAozAv84XSIpZ2idlhDjohv_JpQdfV9B1CQP_a0w81jx8130_assertion type Assertion NP625512.RAozAv84XSIpZ2idlhDjohv_JpQdfV9B1CQP_a0w81jx8130_head.
- NP625512.RAozAv84XSIpZ2idlhDjohv_JpQdfV9B1CQP_a0w81jx8130_assertion description "[The higher signature score in metastatic compared to primary lesions, and the potential link to PI3K activation and EMT, support further studies of ECARS in relation to response to PI3K and EMT inhibitors in clinical trials of metastatic endometrial carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP625512.RAozAv84XSIpZ2idlhDjohv_JpQdfV9B1CQP_a0w81jx8130_provenance.
- NP625512.RAozAv84XSIpZ2idlhDjohv_JpQdfV9B1CQP_a0w81jx8130_assertion evidence source_evidence_literature NP625512.RAozAv84XSIpZ2idlhDjohv_JpQdfV9B1CQP_a0w81jx8130_provenance.
- NP625512.RAozAv84XSIpZ2idlhDjohv_JpQdfV9B1CQP_a0w81jx8130_assertion SIO_000772 24995579 NP625512.RAozAv84XSIpZ2idlhDjohv_JpQdfV9B1CQP_a0w81jx8130_provenance.
- NP625512.RAozAv84XSIpZ2idlhDjohv_JpQdfV9B1CQP_a0w81jx8130_assertion wasDerivedFrom befree-20150227 NP625512.RAozAv84XSIpZ2idlhDjohv_JpQdfV9B1CQP_a0w81jx8130_provenance.
- NP625512.RAozAv84XSIpZ2idlhDjohv_JpQdfV9B1CQP_a0w81jx8130_assertion wasGeneratedBy ECO_0000203 NP625512.RAozAv84XSIpZ2idlhDjohv_JpQdfV9B1CQP_a0w81jx8130_provenance.